BEST OF HEMATOLOGY 2024: Amyloidosis – Dr. Donna Reece
OR
Chair
Dr. Martina Trinkaus
Dr. Matthew Seftel
Panelist
Dr. Donna Reece
Studies/trials discussed:
- Systemic amyloidosis from A (AA) to T (ATTR): a review
- Systemic immunoglobulin light chain amyloidosis
- Characterization of Systemic Amyloid Deposits by Mass Spectrometry
- Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements
- Limited Utility of Mayo 2012 Cardiac Staging System for Risk Stratification of Patients with Advanced Cardiac AL Amyloidosis Analysis of a Uniformly Treated Cohort of 1275 Patients
- Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis
- Identifying Early Suboptimal Hematological Response in Patients with AL Amyloidosis Treated with Bortezomib-Based Chemotherapy
- Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
- Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study
- AL amyloidosis: untangling new therapies
- Role of autologous haematopoietic cell transplantation in the treatment of systemic light chain amyloidosis in the era of anti-CD38 monoclonal antibodies
- Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study
- Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in a Diverse Patient Population with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius
- Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
- Outcomes of Venetoclax-Based Therapy in Patients with Daratumumab-Refractory t(11;14) Positive Light Chain Amyloidosis
- Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies
- Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
- Pooled Analysis of Safety from Birtamimab Phase 1-3 Studies in Patients with Light Chain (AL) Amyloidosis
- Updated OS of patients with AL amyloidosis after CAEL-101.
- Safety and Tolerability of Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia Therapy in Patients with Light-Chain Amyloidosis: 24-Month Results of a Phase 2 Study
- Cael-101 Enhances the Clearance of Light Chain Fibrils and Intermediate Aggregates By Phagocytosis
- Safety and Efficacy of Teclistamab in Patients with Relapsed or Refractory AL Amyloidosis: A Retrospective Case Series
- Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
- Treatment of Al Amyloidosis in Canada
